| Hagerman, Randi J |
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome |
|
|
| Recruiting | 3 | 150 | US | BPN14770/ zatolmilast, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 06/25 | 09/25 | | |
| Recruiting | 3 | 250 | Europe, US, RoW | ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo | Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc. | Fragile X Syndrome | 05/25 | 05/25 | | |
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome |
|
|
| Recruiting | 2/3 | 150 | US | zatolmilast, BPN14770, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 09/25 | 12/25 | | |
| Fleming, Neal W |
NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia |
|
|
| Completed | 3 | 400 | US | HSK3486, Propofol, Diprivan | Haisco-USA Pharmaceuticals, Inc. | General Anesthesia | 11/23 | 11/23 | | |
NCT03075150: PVI as a Parameter to Predict Fluid Responsiveness |
|
|
| Recruiting | N/A | 100 | US | Masimo Rainbow sensor | University of California, Davis, Masimo Corporation | Surgery | 07/19 | 07/19 | | |
NCT04730063: Evaluation of Novel Cardio-Pulmonary Physiological Monitor, the VQm PHM™, for Acute Care Medicine |
|
|
| Recruiting | N/A | 40 | US | VQm PHM™ | Rostrum Medical Innovations Inc., University of California, Davis | Elective Procedures Requiring Mechanical Ventilation | 01/23 | 02/23 | | |
| Apperson, Michelle |
| Recruiting | 3 | 2060 | Europe, Canada, Japan, US, RoW | Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen | Novartis Pharmaceuticals | Relapsing Multiple Sclerosis | 12/27 | 09/28 | | |
|
| Liu, Hong |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04836520: SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. |
|
|
| Completed | 2 | 20 | RoW | SHR6390+anatrozole | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 02/23 | 03/23 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT05881655: Slow Myopia Progression With Different Irradiance Light |
|
|
| Recruiting | N/A | 75 | RoW | Airdoc Red Lighting Device, Repeated Red Light, Low Lever Laser Therapy, Low Intensity Light Therapy, Photobiomodulation Therapy, Seconee, 650nm Red Light, Special Spectacles to Control Myopia, Essilor® Stellest™ Lenses, H.A.L.T lens | Beijing Airdoc Technology Co., Ltd., Shanghai Children's Medical Center | Myopia, Progressive | 05/24 | 12/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Albertson, Timothy |
NCT05354141: Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) |
|
|
| Recruiting | 3 | 970 | US | ExoFlo, Intravenous normal saline | Direct Biologics, LLC | Acute Respiratory Distress Syndrome, ARDS | 03/25 | 08/25 | | |
| Recruiting | 2 | 66 | Europe, US | Reparixin 600mg, REP, Matching Placebo, Control | Dompé Farmaceutici S.p.A, Dompè farmaceutici s.p.a. | Acute Respiratory Distress Syndrome, Adult | 08/25 | 08/25 | | |
| Sandberg, Sarah |
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. |
|
|
| Recruiting | 2 | 270 | Europe, Canada, US, RoW | Buloxibutid, C21, Placebo | Vicore Pharma AB, Population Services International | Idiopathic Pulmonary Fibrosis (IPF) | 02/27 | 03/27 | | |
| Borbe, Abigail Higareda |
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome |
|
|
| Recruiting | 3 | 150 | US | BPN14770/ zatolmilast, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 06/25 | 09/25 | | |
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome |
|
|
| Recruiting | 2/3 | 150 | US | zatolmilast, BPN14770, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 09/25 | 12/25 | | |
| Feldman, Gary |
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome |
|
|
| Recruiting | 3 | 150 | US | BPN14770/ zatolmilast, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 06/25 | 09/25 | | |
| Recruiting | 3 | 250 | Europe, US, RoW | ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo | Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc. | Fragile X Syndrome | 05/25 | 05/25 | | |
| Active, not recruiting | 3 | 196 | Europe, Canada, US, RoW | Ecopipam Hydrochloride | Emalex Biosciences Inc. | Tourette Disorder | 12/24 | 12/24 | | |
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome |
|
|
| Recruiting | 2/3 | 150 | US | zatolmilast, BPN14770, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 09/25 | 12/25 | | |
| Lupercio |
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. |
|
|
| Recruiting | 2 | 270 | Europe, Canada, US, RoW | Buloxibutid, C21, Placebo | Vicore Pharma AB, Population Services International | Idiopathic Pulmonary Fibrosis (IPF) | 02/27 | 03/27 | | |
| Bustos, Ulises |
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome |
|
|
| Recruiting | 3 | 150 | US | BPN14770/ zatolmilast, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 06/25 | 09/25 | | |
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome |
|
|
| Recruiting | 2/3 | 150 | US | zatolmilast, BPN14770, Placebo | Tetra Discovery Partners | Fragile X Syndrome | 09/25 | 12/25 | | |
